Nimotuzumab: Difference between revisions
m Protected "Nimotuzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 32: | Line 32: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 14:19, 20 August 2012
WikiDoc Resources for Nimotuzumab |
Articles |
---|
Most recent articles on Nimotuzumab Most cited articles on Nimotuzumab |
Media |
Powerpoint slides on Nimotuzumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Nimotuzumab at Clinical Trials.gov Clinical Trials on Nimotuzumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Nimotuzumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Nimotuzumab Discussion groups on Nimotuzumab Patient Handouts on Nimotuzumab Directions to Hospitals Treating Nimotuzumab Risk calculators and risk factors for Nimotuzumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Nimotuzumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Nimotuzumab is a humanized monoclonal antibody used to treat cancer. It binds to EGFR (epithelial growth factor receptor).
Template:Humanizedmonoclonals Template:WH Template:WikiDoc Sources